PITPNC1

PITPNC1 is a Class II phosphatidylinositol transfer protein whose lipid-shuttling activity is repurposed across secretory, metabolic, and immune-evasive programs in cancer and physiology (PMID:22822086, PMID:26977884). Biochemically it binds and transfers phosphatidylinositol and phosphatidic acid but, unlike Class I PITPs, does not bind phosphatidylcholine, and its cargo preference shifts toward phosphatidic acid when phospholipase D is active (PMID:22822086). At the Golgi, PITPNC1 binds the resident lipid PI4P and localizes RAB1B, which recruits GOLPH3 to drive Golgi extension and enhanced vesicular release of pro-invasive and pro-angiogenic mediators including HTRA1, MMP1, FAM3C, PDGFA, and ADAM10 (PMID:26977884). PITPNC1 is a transcriptional target of KRAS acting through MEK1/2 and JNK1/2, and it in turn stabilizes MYC protein to control mTOR localization and suppress autophagy (PMID:37210549). It supports tumor cell survival and metastasis through fatty-acid metabolism, enhancing fatty-acid oxidation via CD36 and CPT1B to confer anoikis resistance (PMID:30555557), suppressing reactive oxygen species to promote radioresistance (PMID:32175419), and interacting with FASN to regulate CD155 surface expression and thereby dampen CD8+ T cell killing (PMID:38291470). Beyond cancer, PITPNC1 maintains mitochondrial phospholipid homeostasis in brown adipose tissue, where its loss causes defective β-oxidation and cold-induced hypothermia in knockout mice (PMID:36166181).

1. 2012 High

   Established the core biochemical identity of PITPNC1 by defining which lipids it binds and transfers, distinguishing it from Class I transfer proteins.

   Evidence In vitro lipid binding and transfer assays with purified recombinant protein, permeabilized cell incubations, and phospholipase D activation

   PMID:22822086

   Open questions at the time

   • Structural basis of PA versus PI selectivity not resolved
   • Physiological consequence of lipid transfer not addressed in this study
   • No cellular localization context provided
2. 2016 High

   Connected PITPNC1 lipid binding to a cellular function by showing it binds Golgi PI4P and assembles a RAB1B-GOLPH3 secretory module driving release of pro-metastatic factors.

   Evidence PI4P binding assays, co-immunoprecipitation, localization studies, and loss/gain-of-function with secretion and in vivo metastasis readouts

   PMID:26977884

   Open questions at the time

   • How PA transfer activity relates to PI4P binding at the Golgi unclear
   • Selectivity of secreted cargo not mechanistically explained
3. 2018 Medium

   Extended PITPNC1 function to fatty-acid metabolism, showing it drives anoikis resistance and omental metastasis via FAO upregulation.

   Evidence siRNA/overexpression, adipocyte co-culture, anoikis assays, in vivo metastasis models, and CD36/CPT1B western blotting

   PMID:30555557

   Open questions at the time

   • Mechanism linking PITPNC1 to CD36/CPT1B transcription not defined
   • Single lab; not independently confirmed
   • Connection to its lipid-transfer activity untested
4. 2020 Medium

   Placed PITPNC1 upstream of ROS suppression as a determinant of radioresistance in colorectal cancer.

   Evidence siRNA knockdown in two cell lines, ROS measurement, NAC rescue, and irradiation apoptosis/proliferation assays

   PMID:32175419

   Open questions at the time

   • Molecular mechanism of ROS suppression unidentified
   • No in vivo validation in this study
   • Link to lipid metabolism or secretory function unexplored
5. 2022 High

   Defined a physiological, non-cancer role: PITPNC1 maintains mitochondrial phospholipid homeostasis required for brown adipose thermogenesis.

   Evidence Pitpnc1 knockout mice with cold-exposure phenotyping, lipidomics, and mitochondrial functional assays

   PMID:36166181

   Open questions at the time

   • Mechanism by which PITPNC1 regulates mitochondrial PC/PA balance not resolved
   • Whether direct lipid transfer to mitochondria occurs untested
6. 2023 Medium

   Positioned PITPNC1 within a KRAS-driven signaling axis, identifying both its upstream regulators and a downstream MYC-mTOR-autophagy output.

   Evidence KRAS genetic modulation, MEK1/2 and JNK1/2 pharmacological inhibition, PITPNC1 depletion in vitro/in vivo, RNA-seq, mTOR localization and MYC stability assays

   PMID:37210549

   Open questions at the time

   • Direct mechanism by which PITPNC1 stabilizes MYC not defined
   • Single lab; not independently confirmed
   • Relationship between lipid-transfer activity and MYC stabilization unknown
7. 2024 Medium

   Linked PITPNC1 to tumor immune evasion by showing it interacts with FASN to regulate CD155 and suppress CD8+ T cell function.

   Evidence Co-IP, immunofluorescence co-localization, siRNA/overexpression, tumor cell-T cell co-culture, in vivo models, and flow cytometry

   PMID:38291470

   Open questions at the time

   • Co-IP without reciprocal validation of PITPNC1-FASN interaction
   • How FASN activity drives CD155 surface expression not mechanistically resolved
   • Single lab; not independently confirmed

• How PITPNC1's biochemical lipid-transfer activity mechanistically unifies its diverse downstream roles in secretion, MYC stabilization, ROS suppression, and immune modulation remains unresolved.
• No single mechanistic model connects lipid transfer to the metabolic and signaling phenotypes
• Structural understanding of lipid-cargo regulation across contexts lacking